Pulmonary hypertension in heart failure.
Journal
Current opinion in cardiology
ISSN: 1531-7080
Titre abrégé: Curr Opin Cardiol
Pays: United States
ID NLM: 8608087
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
pubmed:
5
1
2021
medline:
24
4
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
Pulmonary hypertension (PH) occurs frequently in heart failure (HF) and confers worse prognosis. It becomes important to adequately identify these patients to optimize treatment. The purpose of this review is to inform about the updated classification of PH in left heart disease, in addition to current and upcoming trials regarding treatment. The updated classification of PH due to left heart disease now utilizes pulmonary vascular resistance instead of diastolic pulmonary gradient to differentiate between isolated postcapillary and combined pre and postcapillary PH. In regards to treatment, recent clinical trials continue to provide data that pulmonary vasodilators do not improve outcomes in this population. Management of underlying heart disease and optimal control of comorbidities continues to be the mainstay of treatment in PH due to HF. At this time, current data does not support the use of PH-directed therapies.
Identifiants
pubmed: 33394713
doi: 10.1097/HCO.0000000000000834
pii: 00001573-202103000-00013
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
205-210Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
World Health Organization. Chronic cor pulmonale. Report of an expert committe. Wolrd Health Organ Tech Rep Ser 1961; 213:7–32.
Hatano SST. Primary pulmonary hypertension. Report on a WHO Meeting. 1975; Geneva: World Health Organization, 43.
Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34:888–894.
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respiry J 2019; 53:1–13.
Wijeratne TD, Lajkosz K, Brogly SB, et al. Increasing incidence and Prevalence of WHO Groups 1-4 pulmonary hypertension: a population-based cohort study in Ontario, Canada. Circ Cardiovasc Qual Outcomes 2018; 11:1–25.
Rosenkranz S, Gibbs JSR, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016; 37:942–954.
Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction. JACC: Heart Fail 2013; 1:290–299.
Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37:183–188.
Tampakakis E, Leary PJ, Selby VN, et al. The Diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC: Heart Fail 2015; 3:9–16.
Lam CSP, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction. J Am Coll Cardiol 2009; 53:1119–1126.
Shah AM, Shah SJ, Anand IS, et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2014; 7:104–115.
Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am Jf Cardiol 2010; 106:284–286.
Melenovsky V, Hwang S-J, Lin G, et al. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014; 35:3452–3462.
Mohammed SF, Hussain I, AbouEzzeddine OF, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 2014; 130:2310–2320.
Robbins IM, Hemnes AR, Pugh ME, et al. High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 2014; 7:116–122.
Thenappan T, Shah SJ, Gomberg-Maitland M, et al. Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2011; 4:257–265.
Delgado JF, Conde E, Sánchez V, et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005; 7:1011–1016.
Guazzi M, Ghio S, Adir Y. Pulmonary hypertension in HFpEF and HFrEF. J Am Collf Cardiol 2020; 76:1102–1111.
Vachiéry J-L, Adir Y, Barberà JA, et al. Pulmonary hypertension due to left heart diseases. J Amn Collef Cardiol 2013; 62:D100–D108.
Chen Y, Guo H, Xu D, et al. Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease. Hypertension 2012; 59:1170–1178.
Gerges C, Gerges M, Lang MB, et al. Diastolic pulmonary vascular pressure gradient. Chest 2013; 143:758–766.
Gerges M, Gerges C, Pistritto A-M, et al. Pulmonary hypertension in heart failure. epidemiology, right ventricular function, and survival. Am J Respir Crit Care Med 2015; 192:1234–1246.
Anon. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart Jl 2016; 37:67–119.
Naeije R, Vachiery J-L, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013; 41:217–223.
Vachiéry J-L, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respiry J 2019; 53:2–12.
Kovacs G, Avian A, Olschewski A, Olschewski H. Zero reference level for right heart catheterisation. Eur Respir J 2013; 42:1586–1594.
de Oliveira RKF, Ferreira EVM, Ramos RP, et al. Usefulness of pulmonary capillary wedge pressure as a correlate of left ventricular filling pressures in pulmonary arterial hypertension. Jf Heart Lung Transplant 2014; 33:157–162.
Bonno EL, Viray MC, Jackson GR, et al. Modern right heart catheterization: beyond simple hemodynamics. Adv Pulm Hypertens 2020; 19:6–15.
Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555–1562.
Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction. Circulation 2011; 124:164–174.
Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309:1–19.
Hoendermis ES, Liu LCY, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015; 36:2565–2573.
Bermejo J, Yotti R, García-Orta R, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 2018; 39:1255–1264.
Lüscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective Endothelin A (ET A ) receptor blockade in chronic heart failure: the ET A Receptor Blockade Trial (HEAT). Circulation 2002; 106:2666–2672.
Vachiéry J-L, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018; 51:1–9.
Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:347–354.
Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013; 128:502–511.
Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of Riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1). Chest 2014; 146:1274–1285.
Reddy YNV, Obokata M, Koepp K, Borlaug BA. The β-Adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction: a randomized controlled trial. Circ Res 2019; 124:306–314.
Zhang H, Zhang J, Chen M, et al. Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre and post-capillary pulmonary hypertension associated with left heart failure. JACC: Cardiovasc Interv 2019; 12:274–284.
Garcia-Lunar I, Blanco I, Fernández-Friera L, et al. Design of the β3-adrenergic agonist treatment in chronic pulmonary hypertension secondary to heart failure trial. JACC: Basic Transl Sci 2020; 5:317–327.
Pons J, Leblanc M-H, Bernier M, et al. Effects of chronic sildenafil use on pulmonary hemodynamics and clinical outcomes in heart transplantation. J Heart Lung Transplant 2012; 31:1281–1287.
Zakliczynski M, Maruszewski M, Pyka L, et al. Effectiveness and safety of treatment with Sildenafil for secondary pulmonary hypertension in heart transplant candidates. Transplant Proc 2007; 39:2856–2858.
Zimpfer D, Zrunek P, Roethy W, et al. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thoracic Cardiovasc Surg 2007; 133:689–695.
Selim AM, Wadhwani L, Burdorf A, et al. Left ventricular assist devices in pulmonary hypertension Group 2 with significantly elevated pulmonary vascular resistance: a bridge to cure. Heart Lung Circ 2019; 28:946–952.
Park M, Ewald G, Franco V, et al. SOPRANO: Study of macitentan in patients with pulmonary hypertension (PH) post-left ventricular assist device (LVAD) implantation. Circ Res 2016; 124:306–314.